Revance Therapeutics Inc. (NASDAQ:RVNC)’s share price dropped 1.4% during trading on Friday . The stock traded as low as $13.74 and last traded at $13.85, with a volume of 72,556 shares changing hands. The stock had previously closed at $14.04.

RVNC has been the subject of several research analyst reports. Brean Capital reiterated a “buy” rating and set a $48.00 target price on shares of Revance Therapeutics in a research note on Tuesday, May 24th. Guggenheim restated a “buy” rating and set a $55.00 price objective on shares of Revance Therapeutics in a research note on Tuesday, June 14th. Zacks Investment Research cut Revance Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 17th. Piper Jaffray Cos. restated an “overweight” rating and set a $35.00 price objective (down from $54.00) on shares of Revance Therapeutics in a research note on Tuesday, June 14th. Finally, SunTrust Banks Inc. reduced their price objective on Revance Therapeutics from $46.00 to $22.00 and set a “buy” rating on the stock in a research note on Tuesday, June 14th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Revance Therapeutics has a consensus rating of “Buy” and a consensus target price of $39.60.

The firm has a 50 day moving average of $14.17 and a 200 day moving average of $16.59. The company’s market cap is $394.50 million.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.88) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.86) by $0.02. The company earned $0.80 million during the quarter, compared to analyst estimates of $0.06 million. The company’s quarterly revenue was up .0% compared to the same quarter last year. On average, equities research analysts anticipate that Revance Therapeutics Inc. will post ($3.53) EPS for the current fiscal year.

A hedge fund recently bought a new stake in Revance Therapeutics stock. Ameriprise Financial Inc. acquired a new stake in Revance Therapeutics Inc. (NASDAQ:RVNC) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 41,957 shares of the biopharmaceutical company’s stock, valued at approximately $1,433,000. Ameriprise Financial Inc. owned about 0.15% of Revance Therapeutics at the end of the most recent reporting period.

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.